Elite Pharmaceuticals (ELTP) has an interesting high-risk/high-upside setup:
FY2026 revenue: \~$149M, +77%
Operating income: \~$49M, +151%
Profitable with an established manufacturing facility.
Growing portfolio of generic drugs with additional products in development.
Pipeline could provide significant future revenue if approvals and launches succeed.
Current market cap is only around $269M, leaving room for substantial expansion if earnings continue growing.
🚀 Big Bull Thesis
If ELTP can keep launching profitable generics and grow toward $300M–$500M+ revenue, the company could potentially become a multi-billion-dollar pharmaceutical company.
⚠️ Biggest Risk
Generic-drug pricing pressure and competition can rapidly reduce margins. Q1 FY2027 revenue and operating income both declined substantially year-over-year.
Overall: ELTP is a high-risk potential multibagger where the key question is whether its pipeline can consistently replace and expand upon existing products.